奥曲肽联合特异性COX-2抑制剂对肝癌细胞的抑制作用-东南大学学报医学版

奥曲肽联合特异性COX-2抑制剂对肝癌细胞的抑制作用

单位：1.东南大学附属中大医院,消化科,江苏,南京,210009； 2.南京医科大学第一附属医院,老年医学科,江苏,南京,210029

分类号：R735.7, R73-361, R730.53

出版年·卷·期（页码）：2005·24·第六期（363-367）

摘要：

目的:研究特异性环氧化酶-2(COx-2)抑制剂NS-398和生长抑素类似物奥曲肽联合使用对人肝癌细胞系SMMC-7721增殖、凋亡的影响.方法:采用四氮唑盐比色法(MTT法)观察细胞增殖活力改变,流式细胞仪检测细胞凋亡百分率.结果:(1)MTT法显示NS-398和奥曲肽均在一定范围内呈浓度和时间依赖性地抑制SMMC-7721细胞的增殖;联合用药组抑制率显著高于单用NS-398或奥曲肽组(P＜0.01),金正均方法显示q＞1.15,提示两药联合应用有协同抑制肝癌细胞增殖效应,并随着作用时间延长而增强.(2)流式细胞仪测定显示,NS-398、奥曲肽和两药联合作用于SMMC-7721细胞24h后,联合用药组细胞凋亡率显著高于单一用药组(P＜0.01).结论:NS-398和奥曲肽呈剂量、时间依赖性地抑制SMMC-7721细胞增殖,促进SMMC-7721细胞凋亡,两者联合应用具有协同作用.

Objective To investigate the effects of a special COX?2 inhabitor(NS?398) and somastotatin analog(octreotide) on the proliferation and apoptosis in a HCC cell line,SMMC?7721;tofocus on observing the effects of combination treatment of NS?398 and octreotide on antiproliferation and induction of apoptosis in SMMC?7721. Methods Cell growth and proliferation of SMMC?7721 were analyzed with MTT assay; apoptosis was detected with flow cytometry assay.Results (1)NS?398 and octreotide inhibited cell growth of SMMC?7721 in a time-and dose-dependent manner.The combination of 1×10^{-5}mol·L^{-1} NS?398 and 1×10^{-6}mol·L^{-1} octreotide inhibited the proliferation more remarkably than either agent applied singularly((P<)(0.01)),analyzation with Jin Zheng mean square method suggested that(q>)(1.15),and the inhibition rate enhanced along with the time.(2)In apoptosis cell group,Annexin Ⅴ positive cells could be observed with flowcytometry after treatment of NS?398 of 1×10^{-5}mol·L^{-1},octreotide of 1×10^{-6}mol·L^{-1} and the combination of the two group for 24?h respectively.The apoptosis rate of combination group was much greater than that when either one was applied singularly((P<)(0.01)).Conclusion NS?398 and octreotide inhibit SMMC?7721 from growing in a time-and dose-dependent manner;both(NS?398) and octreotide induce the apoptosis of SMMC?7721 remarkably;the combination of the two has a synergistic effect.

参考文献：

[1] SAMUELS B L. Management of recurrent desmoid tumor after surgery and radiation:role of cytotoxic and non-cytotoxic therapies. 1999(4). doi:10.1016/S0960-7404(0)00031-1
[2] KAYE S B, EISENHAUER E A, HAMILTON T C. New noncytotoxic approaches to ovarian cancer, 1999(zk)
[3] SAMONAKIS D N, MOSCHANDREAS J, ARNAOUTIS T. Treatment of hepatocellular caicinoma with long acting somatostatin analogues, 2002
[4] 沈玲, 赵伟, 舒伟平. 肝病专科医院10年来住院病人疾病谱变化的调查. 东南大学学报(医学版)2004(2). doi:10.3969/j.issn.1671-6264.2004.02.009
[5] 金正均. 合并用药中的相加, 1980
[6] SANO H, KAWAHIT Y, WILD R L. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. 1995(17)
[7] TSUJII M, KAWANO S, DUBOIS R N. Cyclooxygenase-expression in human colon cancer cells increases metastatic potential, 1997(7)
[8] SHENG H, SHAO J, MORROW J D. Modulation of apoptosis and bcl-2 expression by prostaglandin E2, 1998(2)
[9] 刘纯伦, 唐承薇, 周旭春. 3种选择性环氧合酶-2抑制剂对肝细胞癌生长的影响. 胃肠病学2004(1). doi:10.3969/j.issn.1008-7125.2004.01.002
[10] TODISCO A, SEVA C, TAKEUCHI Y. Somatostatin inhibits AP-1 function via multiple protein phosphatases, 1959
[11] DING M, DONG Z, CHEN F. Asbestos induces activator protein-1 transactivation in transgenic mice. 1999
[12] HUSSIN S S, SZABO I L, PAI R. MAPK(ERK2) kinase:a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth, 2001

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录